Asterand Inc.
This article was originally published in Start Up
Executive Summary
The executives that head up Asterand Inc. have unconventional CVs for a start-up in the field of genomics. Founder and CEO Randal Charlton was formerly a consultant with the World Bank and various international aid agencies, and president and COO Simon Greenman was the founding VP of operations at MapQuest.com, the oft-consulted Internet source for driving directions. But Charlton's experience in negotiating contracts with the governments of third world countries and Greenman's facility with search engines are exactly the right sort of backgrounds for a company whose mission is creating a global biorepository of human tissue samples to serve pharmaceutical researchers.
You may also be interested in...
Biorepositories
Despite the in silico research ideals of many genomicists, no one has yet found a way around the basic requirement for using human tissue in gene expression studies-a broad array of it, well characterized, from healthy and diseased patients, and from world populations at large. That's why start-ups, drug discovery firms and others are creating a new resource: biorepositories--banks of tissue samples and data to serve the diagnostic, pharmaceutical and tissue engineering industries. As providers of services and products to research-based companies, these companies believe they are operating in a market that ranges from $500 million to $5 billion.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.